Bratton Capital Management, L.P. Denali Therapeutics Inc. Transaction History

Bratton Capital Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$36.89 - $93.56 $16.5 Million - $41.9 Million	-448,035 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$16.01 - $28.82 $8.09 Million - $14.6 Million	-505,000 Reduced 52.99%	448,035 $10.8 Million
Q1 2019 May 15, 2019	SELL	$17.99 - $24.65 $2.86 Million - $3.91 Million	-158,764 Reduced 14.28%	953,035 $22.1 Million
Q4 2018 Feb 14, 2019	BUY	$13.88 - $21.75 $15.4 Million - $24.2 Million	1,111,799 New	1,111,799 $23 Million

226

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.13B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Bratton Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Bratton Capital Management, L.P. with notifications on news.